Journal Mobile Options
Table of Contents
Vol. 72, No. 3, 2011
Issue release date: October 2011
Section title: Original Article
Gynecol Obstet Invest 2011;72:203–207
(DOI:10.1159/000323883)

CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer

Wong R.R.Y.a · Chan L.K.Y.a · Tsang T.P.T.a · Lee C.W.S.b · Cheung T.H.a · Yim S.F.a · Siu N.S.S.a · Lee S.N.C.a · Yu M.Y.c · Chim S.S.C.a · Wong Y.F.a · Chung T.K.H.a
Departments of aObstetrics and Gynaecology, bClinical Pathology, and cAnatomical and Cellular Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR, China

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: 7/28/2010
Accepted: 12/14/2010
Published online: 8/23/2011
Issue release date: October 2011

Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 3

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: http://www.karger.com/GOI

Abstract

Background: The CHD5 gene located on 1p36 encodes a protein – chromodomain helicase DNA-binding protein 5. CHD5 has been shown to be a tumor suppressor gene candidate. This study investigated the involvement of CHD5 in ovarian cancer and its clinicopathological significance. Methods: CHD5 expression in ovarian cancer and its counterpart were determined by quantitative RT-PCR. The correlation of CHD5 expression to clinicopathological features of the tumor was analyzed. Results: CHD5 expression was downregulated by at least twofold in 32 of 72 (41%) invasive epithelial ovarian carcinomas when compared to 12 controls in Hong Kong Chinese women. CHD5 downregulation was correlated to clinical status (p < 0.05), but not to patient age, tumor type and grade, recurrence and clinical stage (p > 0.05). Survival analysis showed that patients with CHD5 downregulation in their tumors were associated with shorter disease-free and total survival times compared to those without CHD5 downregulation (p < 0.05). Cox proportional-hazards regression analysis indicated that downregulation of CHD5 is an independent adverse prognostic factor in ovarian cancer. Conclusion: This study shows that CHD5 is downregulated in a certain number of ovarian cancers and appears to be an adverse predictor candidate of ovarian cancer disease-free and total survival.

© 2011 S. Karger AG, Basel


  

Author Contacts

Prof. Y.F. Wong
Department of Obstetrics and Gynaecology
The Chinese University of Hong Kong, Prince of Wales Hospital
Shatin, NT, Hong Kong, SAR (China)
Tel. +852 2632 2806, E-Mail yickfuwong@cuhk.edu.hk

  

Article Information

R.R.Y.W., L.K.Y.C. and T.P.T.T. contributed equally to this work and are the first authors.

Received: July 28, 2010
Accepted after revision: December 14, 2010
Published online: August 23, 2011
Number of Print Pages : 5
Number of Figures : 3, Number of Tables : 3, Number of References : 9

  

Publication Details

Gynecologic and Obstetric Investigation

Vol. 72, No. 3, Year 2011 (Cover Date: October 2011)

Journal Editor: D'Hooghe T.M. (Leuven)
ISSN: 0378-7346 (Print), eISSN: 1423-002X (Online)

For additional information: http://www.karger.com/GOI


Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: 7/28/2010
Accepted: 12/14/2010
Published online: 8/23/2011
Issue release date: October 2011

Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 3

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: http://www.karger.com/GOI


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.